According to a new research report “Phosphatidylinositol 3-Kinase (PI3K) Inhibitors Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration and Other Developments” published by P&S Intelligence, PI3K inhibitors currently exhibits a strong pipeline with approximately 37 drug candidates.
Explore Report Description at: https://www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysis
PI3K inhibitors pipeline analysis
The PI3K inhibitors pipeline analysis report covers approximately 37 active drug candidates in different stages of development.
Phosphatidylinositol 3-kinases (PI3K) are lipid kinases that are involved in cell regulation, including cell survival, proliferation and differentiation. They act as intermediate molecules in PI3K/AKT/mTOR signaling pathway by sending chemical messengers from cell surface to cytoplasm. These signals activate multiple effector kinase pathways, resulting in survival and growth of normal cells. Phosphatidylinositol 3-kinases is categorized on the basis of classes as class I, II and III, on the basis of structure of the PI3K, based on the specificities of the substrate as well as on the basis of lipid end-product’s nature. Bases on structure, Phosphatidylinositol 3-kinases has four different forms PI3K alpha, PI3K beta, PI3K gamma and PI3K delta.
Positive clinical results from drug candidates targeting PI3K
In March 2017, Bayer AG presented clinical results of Phosphoinositide 3-kinase (PI3K)-targeting drug candidate Copanlisib in Phase II CHRONOS-1 trial, evaluating patients with relapsed or refractory indolent non-Hodgkin's lymphoma (iNHL), trial with NCT ID 01660451. The results across all patient groups showed an objective response rate (ORR) of 59.2%, with a 12% complete response (CR) rate and a median duration of response (DOR) of more than 98 weeks, or 687 days (range 0-687).
Major companies collaborate for the development of PI3K inhibitors pipeline
The research found that different companies engaged in manufacturing of PI3K inhibitors are collaborating. One of the collaborations occurred in November 2016 between Verastem, Inc. and Infinity Pharmaceuticals, Inc.
The major players for PI3K inhibitors pipeline include, but are not limited to, Novartis AG, Genentech, Inc., SignalRX Pharmaceuticals Inc. and others.
PI3K Inhibitors Pipeline Analysis